Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31523348 | 0.82 | CYP11B1 (0.47) | MAOBHTTPDK2 | |
| SCHEMBL27604788 | 0.81 | HSD17B10 (0.41) | HCAR3PTPN1SMN1; SMN2HSD17B10NPC1 | |
| SCHEMBL20594135 | 0.78 | PLA2G4A (0.44) | HCAR3PTPN1MAOBPLA2G4A | |
| SCHEMBL15185681 | 0.77 | HCAR3 (0.42) | HCAR3HSD17B10PLA2G4AHTT | |
| SCHEMBL30159516 | 0.76 | MAOB (0.56) | HCAR3ARMAOBNPC1RAB9A | |
| SCHEMBL1144709 | 0.76 | MAOB (0.56) | HCAR3ARMAOBNPC1RAB9A | |
| SCHEMBL27955207 | 0.76 | HCAR3 (0.41) | HCAR3PTPN1MAOBHSD17B10PLA2G4A | |
| SCHEMBL16292563 | 0.76 | HCAR3 (0.41) | HCAR3MAOBHSD17B10PLA2G4AHTT | |
| SCHEMBL29301511 | 0.75 | HCAR3 (0.42) | HCAR3MAOBHSD17B10PLA2G4AHTT | |
| SCHEMBL30147480 | 0.75 | HCAR3 (0.42) | HCAR3MAOBHSD17B10PLA2G4AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. | 2025-11-13 | — | — | US | disclosed |
| WO-2025054488-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | MOMA THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346600-A1 | TRICYCLIC DERIVATIVES AND RELATED USES | WRN, RECQL, BLM | HCAR3 3754/4885PTPN1 3524/4885SMN1; SMN2 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.